Biomarker development and validationprimary
3 projects
Core business across all three H2020 projects, from thrombosis biomarkers (ThromboSLE) to imaging biomarkers in cancer (PAVE) and MRI applications (SENATOR).
Organization
GOOD BIOMARKER SCIENCES BV
Dutch biomarker SME specializing in molecular imaging, 19F MRI contrast agents, and nanomedicine for cancer and autoimmune diagnostics.
Technology SMEhealthNLSMEThin data (2/5)
H2020 projects
3
As coordinator
1
Total EC funding
€398K
Unique partners
21
What they do
Their core work
Good Biomarker Sciences is a Dutch SME specializing in biomarker development and diagnostic technologies, with particular strength in molecular imaging and nanomedicine. They develop and validate biomarkers for disease assessment — from thrombosis risk in autoimmune conditions to imaging-guided approaches in cancer treatment. Their work bridges diagnostic science and therapeutic monitoring, combining expertise in perfluorocarbon-based MRI contrast agents with nanovaccine platforms for personalized medicine.
Core expertise
What they specialise in
Molecular and MRI imaging technologiesprimary
2 projects
Central to both PAVE (image-guided surgery, molecular imaging) and SENATOR (19F magnetic resonance imaging with nanomaterials).
Nanomedicine and nanovaccine platformssecondary
1 project
Contributed to the PAVE project developing personalized nanomedicine approaches and nanovaccines for pancreatic cancer immunotherapy.
Autoimmune disease diagnosticssecondary
1 project
Coordinated ThromboSLE, focused on accurate thrombosis risk assessment in systemic lupus erythematosus.
Perfluorocarbon-based contrast agentsemerging
1 project
SENATOR project explores 19F perfluorocarbon nanomaterials as MRI contrast agents — a niche but growing field.
Evolution & trajectory
How they've shifted over time
Early focus
Autoimmune disease diagnostics
Recent focus
Imaging-guided nanomedicine
GBS started with a focused clinical diagnostics project (ThromboSLE, 2018) addressing thrombosis risk in autoimmune disease, which they coordinated themselves. From 2019 onward, they shifted decisively toward advanced imaging and nanomedicine, joining larger international consortia working on cancer nanovaccines (PAVE) and 19F MRI technologies (SENATOR). The trajectory shows a clear move from traditional biomarker validation toward imaging-enabled, nanotechnology-driven diagnostics and therapeutics.
GBS is moving from classical biomarker work toward advanced imaging and nanotechnology platforms, positioning themselves at the intersection of diagnostics and image-guided therapy.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European9 countries collaborated
GBS operates primarily as a specialist partner in larger research consortia (2 of 3 projects), bringing focused biomarker and imaging expertise to multi-partner teams. They have coordinated one smaller SME Instrument project (ThromboSLE), demonstrating they can lead when the scope matches their core business. With 21 unique partners across 9 countries from just 3 projects, they integrate well into broad European networks rather than working in closed circles.
Despite only three projects, GBS has built a surprisingly wide network of 21 partners across 9 countries, reflecting the large consortium sizes of MSCA projects. Their partnerships span multiple European countries, suggesting strong international integration for a small Dutch SME.
Why partner with them
What sets them apart
GBS occupies a rare niche as a commercial biomarker company that bridges diagnostic validation with advanced imaging modalities like 19F MRI. Unlike academic imaging groups, they bring a business-oriented perspective to translating imaging biomarkers toward clinical and commercial use. For consortium builders, they offer the combination of SME agility with deep technical knowledge in molecular imaging and nanomaterial-based diagnostics.
Notable projects
Highlights from their portfolio
- PAVELargest project by funding (EUR 265,620), tackling pancreatic cancer with nanovaccine immunotherapy and image-guided surgery — a high-impact therapeutic area.
- ThromboSLEGBS's only coordinated project, an SME Instrument Phase 1 grant validating their own thrombosis diagnostic concept for lupus patients.
- SENATORStaff exchange project exploring 19F perfluorocarbon MRI — a specialized imaging modality with strong future potential in cell tracking and inflammation imaging.
Cross-sector capabilities
Medical imaging technologyNanotechnology and nanomaterialsCancer diagnostics and immunotherapyAutoimmune disease monitoring
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →